IL28B-CC GENOTYPE-RELATED GENE EXPRESSION DURING TREATMENT OF CHRONIC HEPATITIS C (CH-C) WITH PEGYLATED INTERFERON-ALFA (PEG-IFN) AND RIBAVIRIN (RBV): POTENTIAL MECHANISMS FOR SUSTAINED VIROLOGIC RESPONSE (SVR)

被引：2
|
作者：
Younossi, Z. M. [1 ,2 ,3 ]
Estep, J. M. [3 ]
Birerdinc, A. [1 ,2 ]
Stepanova, M. [1 ,3 ]
Baranova, A. [1 ,2 ]
Younossi, I. [1 ]
Afendy, A. [1 ,3 ]
机构：
[1] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA
[2] George Mason Univ, Mol & Microbiol Dept, Ctr Study Genom Liver Dis, Fairfax, VA 22030 USA
[3] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)61354-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1352
引用
收藏
页码：S534 / S534
页数：1
相关论文
共 50 条
  • [21] Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin
    Oze, T.
    Hiramatsu, N.
    Yakushijin, T.
    Kurokawa, M.
    Igura, T.
    Mochizuki, K.
    Imanaka, K.
    Yamada, A.
    Oshita, M.
    Hagiwara, H.
    Mita, E.
    Ito, T.
    Inui, Y.
    Hijioka, T.
    Tamura, S.
    Yoshihara, H.
    Hayashi, E.
    Inoue, A.
    Imai, Y.
    Kato, M.
    Yoshida, Y.
    Tatsumi, T.
    Ohkawa, K.
    Kiso, S.
    Kanto, T.
    Kasahara, A.
    Takehara, T.
    Hayashi, N.
    JOURNAL OF VIRAL HEPATITIS, 2009, 16 (08) : 578 - 585
  • [22] Prediction of early virologic response to treatment with 40KD pegylated (PEG)-interferon (IFN) alfa2a/ribavirin in patients with chronic hepatitis C (genotype 1)
    Ferenci, P
    Jessner, W
    Hackl, F
    Gschwantier, M
    Brunner, H
    Hellmich, B
    Laferi, H
    Stauber, R
    Hubmann, R
    Datz, C
    GASTROENTEROLOGY, 2002, 122 (04) : A626 - A626
  • [23] AN IL28B GENOTYPE-BASED MODEL FOR PERSONALIZED PREDICTION OF RESPONSE TO PEGYLATED-INTERFERON-ALFA AND RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C
    O'Brien, Thomas R.
    Everhart, James E.
    Chung, Raymond T.
    Morgan, Timothy R.
    Bonkovsky, Herbert L.
    Shao, Yongwu
    Lok, Anna S.
    Shiffman, Mitchell L.
    Sninsky, John
    Pfeiffer, Ruth
    HEPATOLOGY, 2010, 52 (04) : 382A - 382A
  • [24] Poor Sustained Virologic Response (SVR) in a Multicenter Real-Life Cohort of Chronic Hepatitis C (CHC) Patients Treated with Pegylated Interferon (PEG IFN) and Ribavirin (RBV) plus Telaprevir (TVR) or Boceprevir (BOC)
    Vo, Kevin P.
    Vutien, Philip
    Akiyama, Matthew J.
    Vu, Vinh D.
    Piotrowski, Joy I.
    Ha, Nghiem B.
    Wantuck, James M.
    Roytman, Marina
    Cheung, Ramsey
    Li, Jiayi
    Tsai, Naoky
    Nguyen, Mindie H.
    HEPATOLOGY, 2014, 60 : 673A - 674A
  • [25] Treatment of chronic hepatitis C in HIV infected patients (pts) with pegylated interferon alpha 2b (PEG-IFN) plus ribavirin (RBV) versus pegylated interferon alpha 2b
    Cargnel, A
    Angeli, E
    Mainini, A
    Casella, A
    Gubertini, G
    Giorgi, R
    Orlando, G
    Duca, PG
    JOURNAL OF HEPATOLOGY, 2003, 38 : 132 - 132
  • [26] Effect of High-Dose Ribavirin (RBV), Alinia (Nitazoxanide) and Pegylated Interferon (pegIFN) Alfa-2a in Attaining Sustained Virologic Response (SVR) in Treatment of Chronic Hepatitis C (ERAIS-C Trial) in Naive Genotype 1 Patients
    Basu, P. Patrick
    Rayapudi, Krishna
    Pacana, Tommy
    Shah, Niraj James
    Krishnaswamy, Nithya
    Brown, Robert S.
    GASTROENTEROLOGY, 2010, 138 (05) : S218 - S218
  • [27] Effect of high-dose ribavirin (RBV), Alinia (Nitazoxanide) and pegylated interferon (PegIFN) alfa-2a in attaining sustained virologic response (SVR) in treatment of chronic hepatitis C (ERAIS-C Trial) in naive genotype 1 patients
    Basu, P. P.
    Rayapudi, K.
    Pacana, T.
    Shah, N. J.
    Krishnaswamy, N.
    Hampole, H.
    Tang, C.
    Brown, R.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : S1 - S2
  • [28] Prospective analysis of sustained virologic response (SVR) to PEG-interferon (PEG IFN) alfa-2b and ribavirin treatment in Asian and Hispanic patients with chronic hepatitis C: Results from the WIN-R trial
    Freilich, Bradley
    Hu, Ke-qin
    Jacobson, Ira
    Brown, Robert
    Afdhal, Nezam
    Kwo, Paul
    Santoro, John
    Becker, Scott
    Wakil, Adil
    Pound, David
    Godofsky, Eliot
    Strauss, Robert
    Bernstein, David
    Flamm, Steven
    Bala, Natarajan
    Araya, Victor
    Griffel, Louis
    Brass, Clifford
    HEPATOLOGY, 2006, 44 (04) : 320A - 321A
  • [29] The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
    Younossi, Zobair M.
    Birerdinc, Aybike
    Estep, Mike
    Stepanova, Maria
    Afendy, Arian
    Baranova, Ancha
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [30] The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
    Zobair M Younossi
    Aybike Birerdinc
    Mike Estep
    Maria Stepanova
    Arian Afendy
    Ancha Baranova
    Journal of Translational Medicine, 10
12345